Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

BIOSANTE PHARMACEUTICALS INC

Form 4 April 19, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person ** LEHMAN LEAH M			2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer		
			BIOSANTE PHARMACEUTICALS INC [bpa]	(Check all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	Director 10% OwnerX_ Officer (give title Other (specify		
111 BARCLA	Y BLVD, SU	UITE 280	04/15/2005	below) below) Vice President, Prod. Dev.		
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
			Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person		
LINCOLNSHIRE, IL 60069				Form filed by More than One Reporting Person		

(City)	(State) (Z	Zip) Table	f, or Beneficial	ly Owned					
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	Cransaction(A) or Disposed of Code (D) Instr. 8) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	04/15/2005		S	377	D	\$ 4.02	80,000	D	
Common Stock	04/18/2005		S	200	D	\$ 3.74	79,800	D	
Common Stock	04/18/2005		S	6,300	D	\$ 3.75	73,500	D	
Common Stock	04/18/2005		S	4,800	D	\$ 3.76	68,700	D	
Common Stock	04/18/2005		S	5,300	D	\$ 3.77	63,400	D	

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

04/18/2005	S	6,900	D	\$ 3.78	56,500	D
04/18/2005	S	6,100	D	\$ 3.79	50,400	D
04/18/2005	S	6,700	D	\$ 3.8	43,700	D
04/18/2005	S	6,700	D	\$ 3.91	37,000	D
04/19/2005	S	900	D	\$ 3.71	36,100	D
04/19/2005	S	1,500	D	\$ 3.72	34,600	D
04/19/2005	S	1,000	D	\$ 3.73	33,600	D
04/19/2005	S	1,500	D	\$ 3.74	32,100	D
04/19/2005	S	6,800	D	\$ 3.75	25,300	D
04/19/2005	S	7,000	D	\$ 3.76	18,300	D
04/19/2005	S	7,800	D	\$ 3.77	10,500	D
04/19/2005	S	5,200	D	\$ 3.78	5,300	D
04/19/2005	S	400	D	\$ 3.8	4,900	D
04/19/2005	S	4,900	D	\$ 3.82	0	D
	04/18/2005 04/18/2005 04/18/2005 04/19/2005 04/19/2005 04/19/2005 04/19/2005 04/19/2005 04/19/2005 04/19/2005 04/19/2005	04/18/2005 S 04/18/2005 S 04/18/2005 S 04/19/2005 S	04/18/2005 S 6,100 04/18/2005 S 6,700 04/18/2005 S 6,700 04/19/2005 S 900 04/19/2005 S 1,500 04/19/2005 S 1,500 04/19/2005 S 6,800 04/19/2005 S 7,000 04/19/2005 S 7,800 04/19/2005 S 5,200 04/19/2005 S 400	04/18/2005 S 6,100 D 04/18/2005 S 6,700 D 04/18/2005 S 6,700 D 04/19/2005 S 900 D 04/19/2005 S 1,500 D 04/19/2005 S 1,500 D 04/19/2005 S 6,800 D 04/19/2005 S 7,000 D 04/19/2005 S 7,800 D 04/19/2005 S 5,200 D 04/19/2005 S 400 D	04/18/2005 S 6,100 D \$ 3.79 04/18/2005 S 6,700 D \$ 3.8 04/18/2005 S 6,700 D \$ 3.91 04/19/2005 S 900 D \$ 3.71 04/19/2005 S 1,500 D \$ 3.72 04/19/2005 S 1,500 D \$ 3.73 04/19/2005 S 6,800 D \$ 3.74 04/19/2005 S 7,000 D \$ 3.76 04/19/2005 S 7,800 D \$ 3.77 04/19/2005 S 5,200 D \$ 3.78 04/19/2005 S 400 D \$ 3.8	04/18/2005 S 6,100 D \$ 3.79 50,400 04/18/2005 S 6,700 D \$ 3.8 43,700 04/18/2005 S 6,700 D \$ 3.91 37,000 04/19/2005 S 900 D \$ 3,71 36,100 04/19/2005 S 1,500 D \$ 3,72 34,600 04/19/2005 S 1,500 D \$ 3,73 33,600 04/19/2005 S 1,500 D \$ 3,74 32,100 04/19/2005 S 6,800 D \$ 3,75 25,300 04/19/2005 S 7,000 D \$ 3,76 18,300 04/19/2005 S 7,800 D \$ 3,77 10,500 04/19/2005 S 5,200 D \$ 3,78 5,300 04/19/2005 S 400 D \$ 3.8 4,900

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exercisable and	7. Title and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	onNumber	Expiration Date	Amount of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/Year)	Underlying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e	Securities	(Instr. 5)	Bene
	Derivative				Securities	S	(Instr. 3 and 4)		Own
	Security				Acquired				Follo
					(A) or				Repo

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

Disposed of (D) (Instr. 3, 4, and 5)

Code V (A) (D) Date Expiration Title Amount

Exercisable Date

Number of Shares

Trans

(Insti

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

LEHMAN LEAH M 111 BARCLAY BLVD **SUITE 280** LINCOLNSHIRE, IL 60069

Vice President, Prod. Dev.

Signatures

/s/ Leah M. Lehman, 04/19/2005 Ph.D.

**Signature of Reporting Date Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).